Dr. Kajino from Digital Unit will give a oral presentation on AI application for drug discovery at the 41st annual meeting of the Japanese society for the study of xenobiotics (JSSX)

2026.10.20

Dr. Kajino from Digital Unit will give an oral presentation on AI application for drug discovery at the 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX), to be held at the Tsukuba International Congress Center, Ibaraki, Japan. If you plan to attend the conference, we invite you to join the session and hear the presentation.

Conference Name: the 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX)

Date & Time: November 18^th, 2026, 9:30-12:00

Location: Symposium 7

Title: AI for Drug Discovery in Practice

Presentation Summary
Recent advances in molecular optimization and molecular property prediction have increased interest in AI for drug discovery.
Despite rapid progress in both computational chemistry and machine learning research, these technologies have not yet been fully integrated into the drug discovery workflow, limiting their practical impact.
In this talk, we will discuss the key barriers to their broader adoption and illustrate practical strategies for overcoming these barriers through case studies.

Axcelead’s Soulution
Axcelead develops proprietary AI models for ADME prediction, activity prediction, and molecular optimization, fully making use of large-scale drug discovery data inherited from pharmaceutical companies. Axcelead not only serves these AI models but also provides integrated drug discovery solutions from hit discovery, hit expansion to lead generation and optimization, leveraging both wet-lab and AI capabilities. For further inquiries on our AI capabilities and potential collaboration, please use our contact form.